(MENAFN- Morocco World News) Rabat - The Ministry of Health is set to authorize the marketing of new generic drugs manufactured in Morocco as part of the implementation of the national policy on drugs and pharmaceuticals. The Ministry has announced that it has authorized a series of generic medicines manufactured in Morocco for the treatment of epilepsy, prostate cancer, sepsis, diarrhea, and cardiovascular. The Ministry indicated that the manufacture of medicine in the country is part of the implementation of the National Drug and Pharmaceutical Policy aimed at providing high-quality, effective, and affordable medicines and encouraging the use of generic drugs. The strategy also aims to give citizens access, particularly the poor, to innovative medicines on a regular and continuous basis and to support the growth of the local pharmaceutical industry, given its strong contribution to national economic development. The ministry recalled that in last June it authorized the commercialization of a generic antiretroviral drug composed of "Tenofovir", which works against the hepatitis B virus (HBV).This benefits the Moroccan laboratories, the pharmaceutical industry, and people suffering from this disease who can benefit from this new generic drug. This new drug, the first generic drug manufactured by a Moroccan laboratory, is available throughout the Kingdom at MAD 289 per pack. It is marketed abroad at MAD 3,000 notes the same source. "Thanks to the commercialization of these new generic drugs, Morocco is consolidating its the rapeutic arsenal necessary for the management of patients suffering from hepatitis B, which reinforces the ambitions and aspirations of the Ministry of Health to end this disease by 2030," concluded the Ministry."
MENAFN2110201701600000ID1095971867
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.